Agennix Announces Appointment of Project Development Manager.

HOUSTON--(BUSINESS WIRE)--March 3, 1999--Agennix Inc. today announced the appointment of Samantha Fast to the position of project development manager, where she will be responsible for managing the clinical development programs of the company.

"We are pleased to add someone with Samantha's qualifications to our staff," said Dr. Denis R. Headon, president and chief executive officer of Agennix. "Her experience will be vital in overseeing the challenging responsibility of managing our worldwide clinical projects. Our therapeutic agent, recombinant human lactoferrin, is currently in phase I/II clinical trials for gastrointestinal and dermatological applications."

Prior to joining Agennix, Fast worked as a process leader at Hoffmann-La Roche Inc. She graduated from the University of New Hampshire with a B.S. in bioscience and technology.

Lactoferrin is an anti-microbial protein that participates in the regulation of the immune response. It is a multi-functional iron-binding protein that displays a number of unique characteristics that lend it to the development of commercially valuable products. It is the second most abundant protein in human milk and is also found at lower levels in other external secretions such as tears, nasal secretions and saliva. Lactoferrin's broad spectrum natural antimicrobial properties combined with its immune regulatory role makes it an ideal product alone as an antimicrobial agent and for enhancing the efficacy of drugs in tackling infectious diseases.

Agennix Inc. is a Houston based biotechnology company engaged in the research and development of a new class of natural anti-inflammatory/anti-infective agents. The company's core underlying technology is built on human lactoferrin, an anti-inflammatory and immunomodulatory protein with applications in the treatment of inflammatory and infectious diseases.